StreetInsider.com News Articles

MitoCareX Bio adds bioinformatician to expand disease-pathway analysis

Mon, 12 Oct 2026 08:07:27 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio Ltd., is expanding its bioinformatics capabilities to include a greater focus on disease-relevant biological pathways within its computational drug-discovery platform, according to a company statement.

As part of the initiative, MitoCareX has added an expert bioinformatician to its scientific team. The company said preliminary analyses are informing the platform's continued development.

The expansion is intended to complement MitoCareX's existing capabilities, which have focused on protein structure, molecular interactions, and structure-guided drug discovery. The developing bioinformatics layer is designed to provide additional context on how potential targets relate to disease-associated

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

Mon, 12 Oct 2026 08:07:00 -0400

MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities

Ness Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, is broadening its existing bioinformatics capabilities to include a greater focus on the analysis of disease-relevant biological pathways within its computational drug-discovery platform.

As part of this initiative, MitoCareX has added an expert bioinformatician to its scientific team. Preliminary analyses generated by the Company

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

Mon, 12 Oct 2026 08:07:00 -0400

MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities

As part of this initiative, MitoCareX has added an expert bioinformatician to its scientific team. Preliminary analyses generated by the Company

MitoCareX Bio moves drug discovery computing to Google Cloud

Wed, 07 Oct 2026 07:32:31 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that MitoCareX Bio Ltd., its wholly owned subsidiary, has deployed its computational drug discovery infrastructure on Google Cloud Platform (GCP).

According to a press release from the Ness Ziona, Israel-based company, the transition is intended to provide MitoCareX with a computing environment designed to support its drug discovery programs. The GCP-based setup is expected to centralize scientific data management, standardize user access permissions, and allow computing and storage resources to scale with project requirements.

David Palach, Chief Executive Officer of Nexentis Technologies, commented on the move: "This deployment is intended to provide MitoCareX's scientific teams with

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

Wed, 07 Oct 2026 07:32:00 -0400

Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs

Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that MitoCareX Bio Ltd. (“MitoCareX”), its wholly owned subsidiary, now deploys its Computational Drug Discovery Infrastructure on Google Cloud Platform (“GCP”).

The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

Wed, 07 Oct 2026 07:32:00 -0400

Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs

The transition is designed to provide MitoCareX with a secure and flexible computing environment for its computational activities and evolving drug discovery requirements. The infrastructure

Form 8-K Nexentis Technologies For: Sep 29

Tue, 06 Oct 2026 09:30:00 -0400

si-local-file:///var/storage/secattach/20261006/27153387.html

Form PRE 14A Nexentis Technologies For: Oct 05

Mon, 05 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261005/27148735.html

MitoCareX adds Bar-Ilan chemistry professor to its advisory board

Thu, 24 Sep 2026 07:50:12 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that Prof. Dan T. Major has joined the Scientific Advisory Board of its wholly owned subsidiary, MitoCareX Bio Ltd., according to a press release issued Sept. 24, 2026.

Prof. Major is a professor of chemistry at Bar-Ilan University in Israel, where his research covers computational chemistry, computational biochemistry, in silico drug development, enzyme design, molecular simulations, and cheminformatics. In his advisory role, he will provide guidance on the evaluation and application of computational chemistry and in silico approaches relevant to drug discovery.

MitoCareX said the appointment supports its efforts to expand internal computational capabilities intended to

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Thu, 24 Sep 2026 07:50:00 -0400

Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities

Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that Prof. Dan T. Major has joined the Scientific Advisory Board (“SAB”) of its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”).

Prof. Major will provide scientific advice to MitoCareX on the evaluation and application

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Thu, 24 Sep 2026 07:50:00 -0400

Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities

Prof. Major will provide scientific advice to MitoCareX on the evaluation and application

MitoCareX Bio begins early-stage review of protein sourcing methods

Wed, 23 Sep 2026 07:09:00 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly-owned subsidiary, MitoCareX Bio Ltd., is evaluating additional commercially available approaches for obtaining proteins used in its in-vitro research activities.

The evaluation focuses on established methods for sourcing proteins and aims to determine whether these approaches meet MitoCareX's research requirements. The company said the assessment is intended to broaden research tools available for its in-vitro activities and maintain flexibility as its drug discovery programs advance.

According to the announcement, the evaluation remains at an early stage. The company noted there is no assurance that any approach under consideration will be adopted or provide anticipated

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Wed, 23 Sep 2026 07:07:00 -0400

Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs

Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities.

MitoCareX is evaluating established, commercially available approaches for obtaining proteins

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Wed, 23 Sep 2026 07:07:00 -0400

MitoCareX is evaluating established, commercially available approaches for obtaining proteins

Form 10-Q Nexentis Technologies For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920940.html

Form 10-Q Nexentis Technologies For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920940.html

Form 8-K Nexentis Technologies For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883732.html

Form 8-K Nexentis Technologies For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883732.html

MitoCareX Bio selects SLC transport protein for drug discovery

Tue, 28 Jul 2026 08:06:38 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio Ltd., has selected a transport protein candidate for a drug discovery campaign, according to a press release dated July 28, 2026.

MitoCareX completed an internal prioritization process to narrow its focus from a broader pool of SLC transport protein candidates previously identified through structural analysis. The selected candidate was identified as having favorable characteristics for inclusion in a drug discovery campaign.

The selection follows a structural analysis of the human SLC transport protein family that MitoCareX conducted outside its mitochondrial program. The company identified proteins it determined were compatible

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE^®-driven discovery strategy

Ness Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has narrowed its focus from the broader pool of SLC transport protein

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Form EFFECT Nexentis Technologies

Mon, 20 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26786524.html

Form EFFECT Nexentis Technologies

Mon, 20 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26786524.html